Skip to main content
    S

    SBC Medical Group Holdings Incorporated (SBC)

    Official site

    INDUSTRIALS • CONSULTING SERVICES • NASDAQ

    $6.18
    -1.17 (-15.92%)

    Market Cap: $755.92M

    Last updated: Nov 17, 2026 at 11:06 AM ET

    SBC Medical Group Holdings Incorporated (SBC) Earnings: Report Dates and Results

    Updated Nov 13, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    SBC Medical Group Holdings (SBC) is expected to report earnings on Mar 25, 2027. In the quarter ended Sep 30, 2026, SBC Medical Group Holdings reported EPS of $0.15, above the $0.11 estimate. It beat the EPS estimate in 5 of the last 8 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    56%(5/9)
    Avg Surprise
    -10.65%
    Streak
    1 Q

    Upcoming Estimates

    Reports Mar 25, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus$0.12
    Range$0.10 - $0.14
    6 analysts
    Revenue Consensus
    $52.04M
    Range$42.65M - $61.22M
    6 analysts

    Next Report

    SBC has an expected report date of Mar 25, 2027. Analysts' consensus for the quarter ending Dec 31, 2026 is 14.3% below the $0.14 reported for the quarter ended Dec 31, 2025.

    SBC Earnings Call

    The latest SBC earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    Earnings History

    Of the 9 quarters below that had an estimate, SBC beat 5 and missed 4. Revenue for the quarter ended Sep 30, 2026 was $58.58M, up 35.1% from $43.35M a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026$0.15$0.11$0.10 - $0.13+36.36%Beat+25.0%42 up, 2 downNov 13, 2026$58.58M
    Jun 30, 2026$0.10$0.12$0.11 - $0.13-16.67%Miss+400.0%41 up, 1 downAug 13, 2026$49.19M
    Mar 31, 2026$0.11$0.10$0.08 - $0.12+10.00%Beat-47.6%40 up, 0 downMay 14, 2026$43.06M
    Dec 31, 2025$0.14$0.11$0.10 - $0.15+27.27%Beat+133.3%40 up, 0 downMar 27, 2026$39.57M
    Sep 30, 2025$0.12$0.11$0.09 - $0.15+9.09%Beat+300.0%30 up, 0 downNov 14, 2025$43.35M
    Jun 30, 2025$0.02$0.14$0.13 - $0.14-85.71%Miss-99.1%21 up, 0 downAug 13, 2025$43.36M
    Mar 31, 2025$0.21$0.11N/A+90.91%BeatN/AN/AN/AMay 15, 2025$47.33M
    Dec 31, 2024$0.06$0.19$0.19 - $0.19-68.42%MissN/A10 up, 0 downMar 28, 2025$44.42M
    Sep 30, 2024$0.03$2.36N/A-98.73%MissN/AN/AN/ANov 13, 2024$53.08M
    Jun 30, 2024$2.33N/AN/AN/AN/A+11156.0%N/AN/AAug 28, 2024$53.10M
    Mar 31, 2024-$0.05N/AN/AN/AN/A-234.9%N/AN/AJun 17, 2024$54.81M
    Dec 31, 2023-$0.04N/AN/AN/AN/A-209.2%N/AN/ADec 31, 2023$146.26M
    Sep 30, 2023-$0.02N/AN/AN/AN/AN/AN/AN/ASep 30, 2023$47.28M
    Jun 30, 2023$0.02N/AN/AN/AN/AN/AN/AN/AJun 30, 2023N/A
    Mar 31, 2023$0.04N/AN/AN/AN/AN/AN/AN/AMar 31, 2023N/A
    Dec 31, 2022$0.04N/AN/AN/AN/AN/AN/AN/AMar 9, 2023N/A
    Sep 30, 2022$0.00N/AN/AN/AN/AN/AN/AN/ANov 14, 2022N/A
    Jun 30, 2022Not reportedN/AN/AN/ANot reportedN/AN/AN/ASep 9, 2022N/A
    Last 18 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was $0.49, down 79.3% from the year before. It was $0.04 for the year ended Dec 31, 2022, the oldest of the 4 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025$0.49-79.3%
    Dec 31, 2024$2.37N/A
    Dec 31, 2023$0.00N/A
    Dec 31, 2022$0.04N/A

    Earnings Calls

    The 2 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 4,000 words across 4 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q3Sep 30, 20263,9594
    2026Q2Jun 30, 20264,9074

    2026Q3 Earnings Call

    Opening remarks

    Hikaru Fukui Moderator Serving as your moderator. Today's presentation materials are posted on our IR website, and the transcript will be posted as soon as it is available. Please note that today's remarks include forward-looking statements. These are not guarantees of future performance, and actual results may differ due to various factors. For details, please refer to our SEC filings. We will also refer to certain non-GAAP measures. Reconciliation to GAAP is provided in today's disclosure materials. Let me walk you through today's program. First, we will show an AI-powered presentation of approximately 10 minutes. Please rest assured that the content has been reviewed in advance. Following the presentation, Yuya Yoshida will share a few remarks, after which we will move to the question-and-answer session. To ask questions, please click the Q&A icon at the bottom of your screen, type your message, and send it. Now, let us begin the presentation.

    Yuya Yoshida CEO Thank you for taking the time to join our conference call today. I will now walk you through our results for the third quarter of fiscal 2026, an update on our business strategy, and our capital and IR. If I had to sum up this quarter in a single sentence, it is the quarter in which SBC's growth clearly re-accelerated. Revenue rose 35% year-on-year. Income from operations grew 66%, and our adjusted EBITDA margin reached 47%. Growth and profitability are improving in tandem, exactly the operating leverage we have been building toward, and a clear demonstration of the strength of our highly profitable MSO model. Let me begin with the clinic highlights, which demonstrate the underlying strength of our business. For the first nine months of the year, same-clinic revenue reached $836 million, up 7% year-on-year, continuing its steady growth. What is particularly encouraging is that our growth is being driven by both more customers and higher spend per visit, rising together. Over the trailing 12 months, we recorded 7.06 million customer visits, up 9% year-on-year, from 2.26 million unique customers, up 10%. At the same time, average spend per visit increased 4% to $290. Our clinic network also expanded by 36 locations year-on-year, reaching 293 locations. In short, our existing clinics are growing stronger while our network continues to expand, a powerful combination for sustainable growth. Next, our financial highlights. Third-quarter revenue was $59 million, up 35% year-on-year. Income from operations was $26 million, up 66%. Adjusted EBITDA was $28 million, also up 66%. And our adjusted EBITDA margin reached 47%, an improvement of 9 points year-on-year. Basic EPS was $0.15, up 25%. Profit grew far faster than revenue, and our operating margin expanded from 37% to 45% year-on-year. This is the operating leverage built into our MSO model.

    Frequently Asked Questions About SBC

    When is SBC Medical Group Holdings's next earnings date?

    SBC Medical Group Holdings's next earnings report is expected for Mar 25, 2027.

    Did SBC beat earnings estimates last quarter?

    Yes. SBC Medical Group Holdings reported EPS of $0.15 for the quarter ended Sep 30, 2026, above the $0.11 estimate, a 36.36% surprise.

    What EPS do analysts expect from SBC next quarter?

    The consensus EPS estimate for SBC Medical Group Holdings for the quarter ending Dec 31, 2026 is $0.12 from 6 analysts, with estimates from $0.10 to $0.14.

    How often does SBC beat earnings estimates?

    SBC Medical Group Holdings beat the EPS estimate in 5 of the last 8 quarters, with an average surprise of +0.35%.